Test Price
2,200 AEDโ Home Collection Available
Heparin Induced Thrombocytopenia (HIT) / Anti-Platelet Factor 4-Heparin (PF4-H) IgG Quantitative Test in UAE
Executive Summary & Core Metrics
This state-of-the-art laboratory assay provides a precise quantitative assessment of IgG-class antibodies directed against the platelet factor 4โheparin complex, the primary diagnostic standard for heparin-induced thrombocytopenia (HIT). We guarantee 99.9% diagnostic accuracy through ISO 9001:2015 accredited processing (Cert: INT/EGQ/2509DA/3139) in full compliance with Dubai Health Authority (DHA) and UAE regulatory frameworks.
- โ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- โ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection โ available daily from 8 AM to 11 PM.
- โ Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation provided by our DHA-licensed clinical team.
- โ Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The Heparin Induced Thrombocytopenia (HIT) / Anti-Platelet Factor 4-Heparin (PF4-H) IgG Quantitative Test is a high-sensitivity chemiluminescent immunoassay (CLIA) designed to detect and quantify IgG-class antibodies directed against the platelet factor 4โheparin complex โ the pathogenic driver of Type II heparin-induced thrombocytopenia. This test is the cornerstone for ruling in or excluding HIT in patients exposed to unfractionated heparin or low-molecular-weight heparin, particularly in post-surgical, cardiac, and critical care settings across UAE hospitals.
| Feature | Our Test โ CLIA (PF4-H IgG Quantitative) | Closest Alternative โ ELISA (PF4-H IgG) |
|---|---|---|
| Precision | High-sensitivity quantitative CLIA with superior signal-to-noise ratio and minimal lot-to-lot variability | Semi-quantitative ELISA with greater inter-assay coefficient of variation |
| Method | Chemiluminescent Immunoassay (CLIA) โ automated, closed-system, ISO 9001:2015 validated | Manual or semi-automated Enzyme-Linked Immunosorbent Assay (ELISA) |
| Speed | Same-day reporting (sample by 11 AM; report same day) | Typically 24โ72 hours turnaround; batch-dependent processing |
| Clinical Specificity | IgG-specific detection โ targets the pathogenic isotype responsible for thrombotic complications | May detect non-pathogenic IgM/IgA in some assay configurations, increasing false-positive rates |
| Regulatory Compliance | Fully compliant with DHA Guidelines, Federal Law No. 2 of 2019, and PDPL 2021 | Variable regulatory alignment; may lack UAE-specific accreditation |
Physician Insight & Safety Protocols
A Note from Dr. Ajay Singh, DHA License: 36234132 โ General Practitioner:
"A positive PF4-H IgG result demands immediate clinical correlation with the 4T pre-test probability score and, where available, functional confirmatory testing. This assay's quantitative output empowers clinicians to stratify thrombotic risk, but no single laboratory value should replace sound clinical judgment at the bedside. I urge every referring physician to interpret these results within the full context of platelet trends, heparin exposure timeline, and any emerging thrombotic manifestations."
Advisory: Anticoagulant Medication Safety
โ ๏ธ CRITICAL SAFETY NOTICE โ Do not discontinue prescribed anticoagulant or antiplatelet medication without consulting your doctor. Abrupt cessation of heparin-based therapy without alternative anticoagulation coverage may precipitate life-threatening thrombotic events, including pulmonary embolism, deep vein thrombosis, or acute limb ischemia. All medication adjustments must be supervised by a DHA-licensed physician.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria โ Do NOT proceed with home collection if any of the following apply:
- Active, uncontrolled hemorrhage or hemodynamic instability requiring urgent hospitalization.
- Known congenital bleeding disorder (e.g., Hemophilia A/B, von Willebrand disease) without prior physician clearance.
- Platelet count below 20,000/ยตL with active mucocutaneous bleeding or any evidence of intracranial hemorrhage.
- Inability to safely access a peripheral vein due to severe burns, cellulitis, or bilateral upper extremity deep vein thrombosis.
Emergency Red Flags โ Seek immediate ER evaluation if you experience:
- Acute-onset skin necrosis, purpura, or painful ecchymoses at heparin injection sites (pathognomonic for HIT with thrombosis).
- Sudden dyspnea, pleuritic chest pain, or hemoptysis โ suggestive of pulmonary embolism.
- Unilateral limb swelling, erythema, and pain โ concerning for acute deep vein thrombosis.
- Acute confusional state, focal neurological deficit, or seizure โ may indicate cerebral venous sinus thrombosis.
- Severe epigastric or flank pain with hypotension โ possible adrenal hemorrhage secondary to adrenal vein thrombosis.
Patient FAQ & Clinical Guidance
1. What is the HIT / Anti-PF4-Heparin IgG Quantitative Test, and why has my doctor ordered it?
This test measures the precise amount of IgG antibodies targeting the platelet factor 4โheparin complex, which are the direct cause of heparin-induced thrombocytopenia โ a serious drug reaction that paradoxically increases clotting risk despite lowering platelet counts. Your doctor likely ordered this test because you are receiving or have recently received heparin therapy (unfractionated or low-molecular-weight heparin) and have developed a significant drop in platelet count, typically occurring 5 to 14 days after heparin exposure. The quantitative result, combined with your clinical 4T score, helps determine whether to discontinue heparin immediately and switch to a non-heparin alternative anticoagulant such as argatroban, danaparoid, or direct oral anticoagulants.
2. How should I prepare for this blood test, and can it be done at home in the UAE?
Overnight fasting is preferred, and you must inform your phlebotomist of all medications โ especially heparin, warfarin, direct oral anticoagulants, and antiplatelet agents โ as these critically influence the clinical interpretation of your results. Yes, home collection is available daily from 8 AM to 11 PM across all Emirates through our ISO-certified cold-chain mobile phlebotomy service. A DHA-licensed phlebotomist arrives at your doorstep with full cold-chain transport capability, ensuring your sodium citrate sample reaches our CLIA analyzer within the validated 4-hour stability window. You will need to complete the mandatory Coagulation Requisition Form (Form 15), which our team can assist with digitally at the time of collection.
3. What do my test results mean, and what happens next after I receive them?
A positive PF4-H IgG result indicates the presence of heparin-dependent antibodies and, when correlated with a high 4T pre-test probability score, strongly supports a diagnosis of heparin-induced thrombocytopenia requiring immediate heparin cessation and alternative anticoagulation. Your quantitative optical density (OD) value will be reported alongside a clinical interpretive comment from our DHA-licensed clinical team. A negative result carries a high negative predictive value (exceeding 95%) and effectively rules out HIT in most clinical scenarios, though rare seronegative cases exist. Regardless of your result, our telephonic post-test clinical guidance service ensures you and your referring physician receive a complete interpretation within hours of report generation.
UAE Regulatory & Data Privacy Adherence
Data Privacy & Protection: All patient-identifiable data is processed and stored in accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL). Test results are released exclusively to the referring physician and the patient through encrypted digital channels with multi-factor authentication.
Health Data Governance: Our operations comply fully with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, ensuring the highest standards of health information confidentiality and security.
Medical Liability Framework: Clinical laboratory practices and patient safety protocols strictly follow Federal Decree-Law No. 4 of 2016 on Medical Liability, safeguarding patient rights and clinical accountability throughout the diagnostic process.
Clinical & Logistical Metadata
| Test Name | Heparin Induced Thrombocytopenia (HIT) / Anti-Platelet Factor 4-Heparin (PF4-H) IgG Quantitative |
| Price (AED) | 2,200 AED |
| Turnaround Time | Same-day reporting (sample by 11 AM; report same day) |
| Sample Type / Matrix | 3 mL whole blood (Sodium Citrate) or Platelet-Poor Plasma (PPP) |
| Methodology Used | Chemiluminescent Immunoassay (CLIA) |
| ICD-10-CM Code | D69.5 (Secondary thrombocytopenia) |
| LOINC Code | 35665-0 (Heparin PF4 Ab.IgG [Units/volume] in Serum or Plasma) |
| DHA Facility License & Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians